论文部分内容阅读
生物治疗对于预后不良的尤因肉瘤(Ewing’s sarcoma,又称尤文肉瘤)患者具有更好的临床意义,其类型包括基因治疗、免疫治疗、抗血管生成靶向治疗等。尤因肉瘤的基因治疗主要体现在反义核酸技术的应用;免疫治疗主要体现在抗体疗法、T细胞疗法、DC疗法和肿瘤疫苗治疗等方面;抗血管生成治疗主要体现在抑制肿瘤血管的生成,从而抑制肿瘤的生长和迁移。随着研究的深入,发现端粒长度的变化、微粒体谷胱甘肽转移酶1(microsomal glutathione S-transferase 1,MGST1)表达水平、肿瘤转移和多药耐药相关基因的表达以及乳头状瘤病毒结合因子等都有可能成为尤因内瘤预后的判断指标。
Biotherapy has better clinical significance for patients with poor prognosis of Ewing’s sarcoma (Ewing’s sarcoma), and its types include gene therapy, immunotherapy, antiangiogenic targeted therapy and the like. Ewing’s sarcoma gene therapy is mainly reflected in the application of antisense nucleic acid technology; immunotherapy is mainly reflected in the antibody therapy, T cell therapy, DC therapy and tumor vaccine treatment and so on; anti-angiogenic therapy is mainly reflected in the inhibition of tumor angiogenesis, Thus inhibiting tumor growth and migration. With the deepening of the research, the changes of telomere length, the expression of microsomal glutathione S-transferase 1 (MGST1), the expression of tumor metastasis and multidrug resistance genes and the expression of papilloma Virus binding factors are likely to be a prognostic indicator of Ewing’s tumor.